vs
Orthofix Medical Inc.（OFIX）与猫途鹰（TRIP）财务数据对比。点击上方公司名可切换其他公司
猫途鹰的季度营收约是Orthofix Medical Inc.的1.9倍（$411.0M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -9.2%，领先8.2%），Orthofix Medical Inc.同比增速更快（2.0% vs 0.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-122.0M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
TripAdvisor是美国知名在线旅游服务企业，旗下运营在线旅行社平台、旅游产品比价网站及移动应用，平台拥有大量用户生成的真实旅行内容，为全球消费者提供出行规划、预订等多元服务。
OFIX vs TRIP — 直观对比
营收规模更大
TRIP
是对方的1.9倍
$219.9M
营收增速更快
OFIX
高出2.0%
0.0%
净利率更高
OFIX
高出8.2%
-9.2%
自由现金流更多
OFIX
多$138.8M
$-122.0M
两年增速更快
OFIX
近两年复合增速
2.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $411.0M |
| 净利润 | $-2.2M | $-38.0M |
| 毛利率 | 71.1% | 91.5% |
| 营业利润率 | 0.2% | -8.3% |
| 净利率 | -1.0% | -9.2% |
| 营收同比 | 2.0% | 0.0% |
| 净利润同比 | 92.4% | -3900.0% |
| 每股收益（稀释后） | $-0.05 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXTRIP
| Q4 25 | $219.9M | $411.0M | ||
| Q3 25 | $205.6M | $553.0M | ||
| Q2 25 | $203.1M | $529.0M | ||
| Q1 25 | $193.6M | $398.0M | ||
| Q4 24 | $215.7M | $411.0M | ||
| Q3 24 | $196.6M | $532.0M | ||
| Q2 24 | $198.6M | $497.0M | ||
| Q1 24 | $188.6M | $395.0M |
净利润OFIXTRIP
| Q4 25 | $-2.2M | $-38.0M | ||
| Q3 25 | $-22.8M | $53.0M | ||
| Q2 25 | $-14.1M | $36.0M | ||
| Q1 25 | $-53.1M | $-11.0M | ||
| Q4 24 | $-29.1M | $1.0M | ||
| Q3 24 | $-27.4M | $39.0M | ||
| Q2 24 | $-33.4M | $24.0M | ||
| Q1 24 | $-36.0M | $-59.0M |
毛利率OFIXTRIP
| Q4 25 | 71.1% | 91.5% | ||
| Q3 25 | 72.2% | 92.6% | ||
| Q2 25 | 68.7% | 92.1% | ||
| Q1 25 | 62.8% | 93.2% | ||
| Q4 24 | 69.0% | 93.4% | ||
| Q3 24 | 68.7% | 92.5% | ||
| Q2 24 | 67.8% | 92.8% | ||
| Q1 24 | 67.5% | 93.7% |
营业利润率OFIXTRIP
| Q4 25 | 0.2% | -8.3% | ||
| Q3 25 | -8.3% | 12.7% | ||
| Q2 25 | -7.9% | 11.2% | ||
| Q1 25 | -25.2% | -3.8% | ||
| Q4 24 | -5.3% | 0.2% | ||
| Q3 24 | -9.6% | 13.2% | ||
| Q2 24 | -12.5% | 7.2% | ||
| Q1 24 | -15.6% | -3.8% |
净利率OFIXTRIP
| Q4 25 | -1.0% | -9.2% | ||
| Q3 25 | -11.1% | 9.6% | ||
| Q2 25 | -6.9% | 6.8% | ||
| Q1 25 | -27.4% | -2.8% | ||
| Q4 24 | -13.5% | 0.2% | ||
| Q3 24 | -13.9% | 7.3% | ||
| Q2 24 | -16.8% | 4.8% | ||
| Q1 24 | -19.1% | -14.9% |
每股收益（稀释后）OFIXTRIP
| Q4 25 | $-0.05 | $-0.32 | ||
| Q3 25 | $-0.57 | $0.43 | ||
| Q2 25 | $-0.36 | $0.28 | ||
| Q1 25 | $-1.35 | $-0.08 | ||
| Q4 24 | $-0.76 | $0.03 | ||
| Q3 24 | $-0.71 | $0.27 | ||
| Q2 24 | $-0.88 | $0.17 | ||
| Q1 24 | $-0.95 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $1.0B |
| 总债务越低越好 | — | $819.0M |
| 股东权益账面价值 | $450.0M | $645.0M |
| 总资产 | $850.6M | $2.6B |
| 负债/权益比越低杠杆越低 | — | 1.27× |
8季度趋势，按日历期对齐
现金及短期投资OFIXTRIP
| Q4 25 | $82.0M | $1.0B | ||
| Q3 25 | $62.9M | $1.2B | ||
| Q2 25 | $65.6M | $1.2B | ||
| Q1 25 | $58.0M | $1.2B | ||
| Q4 24 | $83.2M | $1.1B | ||
| Q3 24 | $30.1M | $1.1B | ||
| Q2 24 | $26.4M | $1.2B | ||
| Q1 24 | $27.0M | $1.2B |
总债务OFIXTRIP
| Q4 25 | — | $819.0M | ||
| Q3 25 | $157.2M | $821.0M | ||
| Q2 25 | $157.0M | $822.0M | ||
| Q1 25 | $156.9M | $1.2B | ||
| Q4 24 | $157.0M | $831.0M | ||
| Q3 24 | $118.5M | $832.0M | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXTRIP
| Q4 25 | $450.0M | $645.0M | ||
| Q3 25 | $442.5M | $707.0M | ||
| Q2 25 | $458.3M | $627.0M | ||
| Q1 25 | $458.3M | $643.0M | ||
| Q4 24 | $503.1M | $943.0M | ||
| Q3 24 | $525.9M | $944.0M | ||
| Q2 24 | $546.0M | $857.0M | ||
| Q1 24 | $570.3M | $825.0M |
总资产OFIXTRIP
| Q4 25 | $850.6M | $2.6B | ||
| Q3 25 | $832.6M | $2.8B | ||
| Q2 25 | $837.2M | $2.9B | ||
| Q1 25 | $823.1M | $2.8B | ||
| Q4 24 | $893.3M | $2.6B | ||
| Q3 24 | $867.9M | $2.7B | ||
| Q2 24 | $882.0M | $2.8B | ||
| Q1 24 | $906.0M | $2.7B |
负债/权益比OFIXTRIP
| Q4 25 | — | 1.27× | ||
| Q3 25 | 0.36× | 1.16× | ||
| Q2 25 | 0.34× | 1.31× | ||
| Q1 25 | 0.34× | 1.81× | ||
| Q4 24 | 0.31× | 0.88× | ||
| Q3 24 | 0.23× | 0.88× | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $-103.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-122.0M |
| 自由现金流率自由现金流/营收 | 7.6% | -29.7% |
| 资本支出强度资本支出/营收 | 4.9% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $163.0M |
8季度趋势，按日历期对齐
经营现金流OFIXTRIP
| Q4 25 | $27.7M | $-103.0M | ||
| Q3 25 | $12.4M | $44.0M | ||
| Q2 25 | $11.6M | $202.0M | ||
| Q1 25 | $-18.4M | $102.0M | ||
| Q4 24 | $23.7M | $-3.0M | ||
| Q3 24 | $11.7M | $-43.0M | ||
| Q2 24 | $9.0M | $51.0M | ||
| Q1 24 | $-18.6M | $139.0M |
自由现金流OFIXTRIP
| Q4 25 | $16.8M | $-122.0M | ||
| Q3 25 | $2.5M | $25.0M | ||
| Q2 25 | $4.5M | $177.0M | ||
| Q1 25 | $-25.1M | $83.0M | ||
| Q4 24 | $15.2M | $-26.0M | ||
| Q3 24 | $6.3M | $-63.0M | ||
| Q2 24 | $-360.0K | $36.0M | ||
| Q1 24 | $-29.1M | $123.0M |
自由现金流率OFIXTRIP
| Q4 25 | 7.6% | -29.7% | ||
| Q3 25 | 1.2% | 4.5% | ||
| Q2 25 | 2.2% | 33.5% | ||
| Q1 25 | -13.0% | 20.9% | ||
| Q4 24 | 7.0% | -6.3% | ||
| Q3 24 | 3.2% | -11.8% | ||
| Q2 24 | -0.2% | 7.2% | ||
| Q1 24 | -15.4% | 31.1% |
资本支出强度OFIXTRIP
| Q4 25 | 4.9% | 4.6% | ||
| Q3 25 | 4.8% | 3.4% | ||
| Q2 25 | 3.5% | 4.7% | ||
| Q1 25 | 3.5% | 4.8% | ||
| Q4 24 | 4.0% | 5.6% | ||
| Q3 24 | 2.7% | 3.8% | ||
| Q2 24 | 4.7% | 3.0% | ||
| Q1 24 | 5.6% | 4.1% |
现金转化率OFIXTRIP
| Q4 25 | — | — | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 5.61× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.00× | ||
| Q3 24 | — | -1.10× | ||
| Q2 24 | — | 2.13× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
TRIP
| Third Party | $327.0M | 80% |
| The Fork | $58.0M | 14% |
| Other | $26.0M | 6% |
